Analysts have been eager to weigh in on the Healthcare sector with new ratings on Corvus Pharmaceuticals (CRVS – Research Report) and Caribou Biosciences (CRBU – Research Report).
Corvus Pharmaceuticals (CRVS)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Corvus Pharmaceuticals, with a price target of $3.50. The company’s shares closed last Wednesday at $0.69.
According to TipRanks.com, Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Corvus Pharmaceuticals with a $3.50 average price target.
See today’s best-performing stocks on TipRanks >>
Caribou Biosciences (CRBU)
Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Caribou Biosciences today and set a price target of $29.00. The company’s shares closed last Wednesday at $4.80.
According to TipRanks.com, Cann ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $27.00, which is a 463.7% upside from current levels. In a report issued on March 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRVS:
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Corvus Pharmaceuticals Inc. (CRVS) Q4 Earnings Cheat Sheet
- Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023
- Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting
- Corvus Pharmaceuticals announces new data on CPI-818
